Armed with cash, Bel­gian iP­SC play­er makes a play for Celyad’s cell ther­a­py man­u­fac­tur­ing site

A Bel­gian cell ther­a­py play­er has net­ted a deal close to home.

Ncar­dia, a Bel­gium-based con­tract re­search com­pa­ny, spun out its cell ther­a­py and man­u­fac­tur­ing arm in April in­to a com­pa­ny called Cel­lis­tic. Now, the spin-out has ac­quired an 11,000-square-foot fa­cil­i­ty in the town of Mont-Saint-Guib­ert, Bel­gium, for the price of €6 mil­lion ($5.9 mil­lion) from Celyad On­col­o­gy. The deal is ex­pect­ed to close in Q2 of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER